Literature DB >> 27845219

Efficacy of Daily Low-dose Tadalafil for Treating Overactive Bladder: Results of a Randomized, Double-blind, Placebo-controlled Trial.

Hongde Chen1, Feng Wang2, Zhixian Yu2, Yirong Zhang2, Chaohui Liu3, Shengjie Dai4, Bicheng Chen5, Jiaju Lv6.   

Abstract

OBJECTIVE: To evaluate the efficacy of daily low-dose tadalafil therapy for overactive bladder (OAB) in women. PATIENTS AND METHODS: A total of 96 women with idiopathic OAB from 3 medical centers in the south of Zhejiang Province of China were randomly assigned to treatment with daily low-dose tadalafil (5 mg, n = 48) or placebo (n = 48) for 3 months. The Indevus Urgency Severity Scale, overactive bladder symptom score (Homma et al, 2006), and a 3-day micturition diary with frequency, incontinence, and urgency episodes were recorded and compared before the treatment, every 2 weeks following the treatment, and 3 months after the treatment. Uroflowmetry and transabdominal ultrasound were also conducted following the treatment to determine the maximum flow rate, voided volume, postvoid residual volume, total bladder capacity, and voiding efficiency. The patient's overall rating of improvement in symptoms was assessed as well.
RESULTS: The overactive bladder symptom score significantly decreased, and the frequency, incontinence, and urgency episodes significantly improved in the tadalafil treatment group as compared with the placebo group and baselines at weeks 4, 6, 8, 10, and 12, as well as 3 months posttreatment (P <.05). In addition, voided volume and total bladder capacity obviously increased in the treatment group (P <.05). The Indevus Urgency Severity Scale decreased from week 4 to 3 months posttreatment in the treatment group (P <.05). No changes were found in the maximum flow rate, postvoid residual volume, and voiding efficiency. All adverse symptoms were mild to moderate.
CONCLUSION: Daily low-dose tadalafil is a considerable, well-tolerated, and effective treatment for OAB in women.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27845219     DOI: 10.1016/j.urology.2016.11.008

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  8 in total

Review 1.  [Overactive bladder-which treatment when?]

Authors:  J Pannek
Journal:  Urologe A       Date:  2017-12       Impact factor: 0.639

Review 2.  Management of Overactive Bladder Symptoms After Radical Prostatectomy.

Authors:  Benoit Peyronnet; Benjamin M Brucker
Journal:  Curr Urol Rep       Date:  2018-10-10       Impact factor: 3.092

3.  Advances in pharmacotherapy for the treatment of overactive bladder.

Authors:  Caitlyn E Painter; Anne M Suskind
Journal:  Curr Bladder Dysfunct Rep       Date:  2019-11-25

Review 4.  Drugs Currently Undergoing Preclinical or Clinical Trials for the Treatment of Overactive Bladder: A Review.

Authors:  Silvia Joseph; Steffi A Maria; Jacob Peedicayil
Journal:  Curr Ther Res Clin Exp       Date:  2022-04-06

5.  Tadalafil ameliorates bladder overactivity by restoring insulin-activated detrusor relaxation via the bladder mucosal IRS/PI3K/AKT/eNOS pathway in fructose-fed rats.

Authors:  Wei-Chia Lee; Steve Leu; Kay L H Wu; You-Lin Tain; Yao-Chi Chuang; Julie Y H Chan
Journal:  Sci Rep       Date:  2021-04-15       Impact factor: 4.379

Review 6.  Update on the management of overactive bladder.

Authors:  Christina Fontaine; Emma Papworth; John Pascoe; Hashim Hashim
Journal:  Ther Adv Urol       Date:  2021-08-31

7.  Efficacy of a combination of dutasteride, tadalafil, and solifenacin in the treatment of previously unsuccessful patients.

Authors:  Kirill Kosilov; Irina Kuzina; Vladimir Kuznetsov; Olga Barabash; Ekaterina Fedorishcheva
Journal:  Asian J Urol       Date:  2021-04-20

Review 8.  Recent advances in managing overactive bladder.

Authors:  George Araklitis; Georgina Baines; Ana Sofia da Silva; Dudley Robinson; Linda Cardozo
Journal:  F1000Res       Date:  2020-09-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.